Skip to content
OpenCapital
Get started

Immunome IMNM Enterprise value

Enterprise value at other companies

Pfizer logo
PfizerPFE
$222.4B+9.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2.62B+275%
Nuvation Bio logo
Nuvation BioNUVB
$1.42B+154%
SELLAS Life Sciences Group, Inc. logo
SELLAS Life Sciences Group, Inc.SLS
$653.41M+826%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$2.8B+110%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$8.16B+187%

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.19B+323%
P/S545.2×+498×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0×0.0×
Current ratio21.7×+11.2×

Where this comes from

Calculated from Immunome’s reported figures.

$2.5Bmarket cap+$3.7Mtotal debt−$582.7Mcash and equivalents=$1.9B

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunome's enterprise value?
Immunome (IMNM) reported enterprise value of $1.9B in Q1 2026.
How has Immunome's enterprise value changed year-over-year?
Immunome's enterprise value increased by 470.3% year-over-year, from $332.33M to $1.9B.
What is the long-term trend for Immunome's enterprise value?
Over 4 years (2020 to 2025), Immunome's enterprise value has grown at a 116.8% compound annual growth rate (CAGR), from $77.87M to $1.72B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.